false 0001446847 0001446847 2024-06-21 2024-06-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

June 21, 2024

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34620   04-3404176
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)     Identification Number)

 

100 Summer Street, Suite 2300        
Boston, Massachusetts       02110
(Address of principal
executive offices)
      (Zip code)

 

(617) 621-7722 

(Registrant’s telephone number,

including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value IRWD Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 18, 2024, Ironwood Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the Annual Meeting are as follows:

 

1.The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes:

 

Director Nominee  For  Withheld  Broker Non-Votes
Mark Currie, Ph.D.  130,019,704  5,472,128  7,708,364
          
Alexander Denner, Ph.D.  125,450,072  10,041,760  7,708,364
          
Andrew Dreyfus  129,704,783  5,787,049  7,708,364
          
Jon Duane  127,436,834  8,054,998  7,708,364
          
Marla Kessler  130,081,722  5,410,110  7,708,364
          
Thomas McCourt  133,639,699  1,852,133  7,708,364
          
Julie McHugh  124,822,215  10,669,617  7,708,364
          
Catherine Moukheibir  129,803,799  5,688,033  7,708,364
          
Jay Shepard  133,672,033  1,819,799  7,708,364

 

2.The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes:

 

For  Against  Abstain  Broker Non-Votes
127,439,687  7,953,508  98,637  7,708,364

 

3.The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2024, based on the following votes:

 

For  Against  Abstain  Broker Non-Votes
136,781,986  6,305,538  112,672  -

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Ironwood Pharmaceuticals, Inc.
       
       
   Dated: June 21, 2024   By: /s/ Sravan K. Emany
      Name: Sravan K. Emany
      Title: Senior Vice President, Chief Financial Officer